Clinical trial

Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)

NCT07550920

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-05-10

PhasePHASE2

Study timeline

Study start (estimated)2026-05-10Date precision: day

Registry last updated2026-04-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

Interventions

Drug: Retlirafusp alfaDRUG

Drug: Single-agent ChemotherapyDRUG

Procedure: Radical SurgeryOTHER

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07550920 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.